Steady erosion not dramatic plunge likely as Actos faces first generics in Japan
This article was originally published in Scrip
Executive Summary
This month's delayed reimbursement price listing of generic products in Japan will include the first such competition to Takeda's big selling oral antidiabetic Actos (pioglitazone), with Sawai and Towa Yakuhin among the leading local firms in the sector set to enter the fray.